Regeneron Pharmaceuticals (REGN)
$385.94 0.37 (0.10%)
17:49 EST REGN Stock Quote Delayed 15 Minutes
Previous Close $385.94
Market Cap 40.89B
PE Ratio 31.28
Volume (Avg. Vol.) 862,700
Day's Range 382.53 - 386.60
52-Week Range 271.37 - 442.00
Dividend & Yield N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
Thursday's big stock charts detail the hopes for 3 stocks trying to recover from multi-year lows.
Regeneron Pharmaceuticals (REGN) earnings for the biotechnology company's third quarter of 2019 have REGN stock soaring on Tuesday.
Cara stock is up ahead of its presentations at Kidney Week 2019. Unless it reports bad news, Cara Therapeutics looks ready to run.
Of the undervalued stocks that Goldman Sachs recently thrust into the spotlight, these three are the most promising stocks to buy. Here's what you need to know about each.
Biotech stocks are still out of favor because of macro uncertainties. But beneath that, investors may find companies trading at deep value.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Investors saw new highs in the Nasdaq today, but the index finished slightly lower on the day. Here's what we're watching now.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.
While some companies are doing a good job closing their CEO-Worker wage gaps, these seven companies are not.
When drug companies fall out of favor, as now, I look first to companies with a method for drug discovery like Regeneron stock.
Big pharma stocks are getting good coverage from JPMorgan's healthcare event. Here are three undervalued pharmaceutical stocks to buy now.
It might seem like an odd pairing, but WING and REGN stock have similar leadership qualities off and on the price chart.
From Market News Video
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Southern Company (SO), where a total volume of 26,230 contracts has been traded thus far today, a contract volume which is representative of approximately 2.6 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 60.9% of SO's average daily trading volume over the past month, of 4.3 million shares..
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader